EMA backs oral GLP-1 tablet for obesity and type 2 diabetes
The European Medicines Agency has recommended Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults living with obesity or overweight, and for adults with type 2 diabetes whose blood glucose remains inadequately controlled. The CHMP opinion does not itself grant access, but it moves the medicine one step closer to an EU-wide marketing authorisation and, eventually, national pricing and reimbursement decisions.
For clinicians, the appeal is obvious: a GLP-1 therapy delivered as a tablet rather than an injection. In a class long defined by subcutaneous dosing, the oral route may lower a practical barrier that has limited uptake in real-world obesity and diabetes care. It also broadens the therapeutic conversation for patients who need chronic treatment but are unwilling or unable to use injectable agents.
GLP-1 biology fits the needs of both diseases. By activating receptors for the incretin hormone, orforglipron reduces appetite, increases satiety, and improves glycaemic control through glucose-dependent insulin secretion and reduced glucagon release. The pharmacologic logic is direct: less caloric intake for weight management, better postprandial and fasting glucose handling for diabetes, and a mechanism that aligns with two disorders that frequently travel together.
Weight loss endpoints favored the active drug over placebo
The recommendation for weight management rests on two studies enrolling 4,740 adults with obesity or overweight. One study included participants without type 2 diabetes but with another weight-related health problem; the other enrolled adults with type 2 diabetes. After 72 weeks, people treated with Foundayo lost about 5% to 11% of body weight, depending on dose, while those receiving placebo lost about 2% to 2.5%.
Those differences are clinically meaningful because obesity treatment is rarely only about scale weight. Modest-to-moderate weight loss can improve blood pressure, sleep-disordered breathing, glycaemic burden, mobility, and long-term cardiometabolic risk, even before a patient reaches the sort of larger reductions often associated with bariatric procedures. A drug that can push weight loss beyond placebo by several percentage points over more than a year enters a crowded but still consequential therapeutic space.
Dose response matters here. The reported range suggests a stepwise effect rather than a flat class response, which is important for individualizing treatment when tolerability and efficacy must be balanced. In practice, that kind of gradient can determine whether a patient continues therapy, escalates dose, or stops because the benefits never outrun the gastrointestinal adverse effects.
HbA1c reductions reached the range expected for a potent incretin therapy
The diabetes program was larger still, with four main studies involving 3,765 adults whose blood glucose remained inadequately controlled with diet and physical activity alone or in combination with other diabetes medicines. Across those trials, Foundayo was used either alone or with other glucose-lowering therapies and was compared with placebo, dapagliflozin, or oral semaglutide. The main efficacy endpoint was the change in HbA1c, the standard long-term marker of glycaemic control.
Across studies, HbA1c fell by about 1.2 to 1.9 percentage points with Foundayo, depending on dose. The comparator effects were smaller: 0.4 to 0.8 percentage points with placebo, 0.8 percentage points with dapagliflozin 10 mg, and 1.2 to 1.5 percentage points with oral semaglutide at 7 mg and 14 mg, respectively. Those numbers place orforglipron in a range that should attract attention from endocrinologists, particularly in patients who need stronger glycaemic lowering without moving straight to injectable therapy.
A one-sentence takeaway from the diabetes data is hard to avoid: the tablet lowered HbA1c more than placebo and, in the comparisons provided, performed at least comparably to established oral options. In a disease where treatment sequencing is often slowed by adherence, injection hesitancy, or patient preference, oral incretin therapy can shift the first few therapeutic decisions.
Gastrointestinal effects were common during dose escalation
Nausea, vomiting, and diarrhoea were the most common adverse effects. These reactions occurred more often while the dose was being increased and became less frequent over time.
That pattern is familiar for GLP-1 therapy and reflects on-target pharmacology rather than an unexpected toxicity signal. Slowing gastric emptying, altering gut-brain satiety signaling, and changing appetite perception often carry a gastrointestinal cost early in treatment. For patients, the practical question is whether gradual titration can preserve enough tolerability for continuation, because discontinuation during escalation is where otherwise promising metabolic therapies often lose their real-world effect.
The article does not provide discontinuation rates, serious adverse event counts, or head-to-head superiority claims beyond the comparator efficacy figures. Those missing details matter when translating trial efficacy into routine care, especially for people with multimorbidity, frailty, or a prior history of poor tolerance to incretin-based medicines. Without those data, the strongest statement is still the simplest one: the medicine lowered weight and HbA1c, and it did so with the expected class-related gastrointestinal burden.
EU review moves the drug toward country-level access decisions
The CHMP opinion is only an intermediary step. The next stage runs through the European Commission, which will decide on an EU-wide marketing authorisation. After that, each Member State will determine price and reimbursement according to its own health system, budget constraints, and clinical priorities.
That sequence will shape uptake as much as the trial data. In obesity care, access often hinges less on pharmacology than on reimbursement criteria, prior authorisation rules, and the willingness of national systems to treat obesity as a chronic disease rather than a lifestyle choice. In diabetes, the question is different but equally practical: where a once-daily oral GLP-1 fits among metformin, SGLT2 inhibitors, oral semaglutide, and injectable incretin therapies.
The application comes from Eli Lilly Nederland B.V., and the active substance is a small non-peptide molecule designed for oral use. Its non-peptide structure is not a cosmetic detail; it is what makes a GLP-1 receptor agonist feasible as a tablet rather than an injection. For patients who have resisted injectable treatment, that may prove to be the most important feature of all.
The remaining uncertainty is not whether orforglipron can move weight and HbA1c in the right direction. It can. The open questions now sit with long-term safety, persistence, comparative effectiveness in broader practice, and whether national payers will treat an oral GLP-1 as a widely usable metabolic tool or a narrowly reserved option after existing therapies fail.